Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated March 3, 2025, reports on the full results of the ANCHOR-1 and ANCHOR-2 Phase III clinical trials for depemokimab. The data was presented at the 2025 AAAAI/WAO Joint Congress and published in The Lancet. The filing focuses on the respiratory and immunology pipeline rather than general corporate financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a clinical trial update and does not contain financial statements.
Material Changes and Clinical Results
The filing details significant clinical advancements for depemokimab, an investigational ultra-long-acting monoclonal antibody targeting interleukin-5 (IL-5) for chronic rhinosinusitis with nasal polyps (CRSwNP):
- Primary Endpoints Met: Both ANCHOR-1 (N=271) and ANCHOR-2 (N=257) met co-primary endpoints. Twice-yearly dosing showed statistically significant improvements in nasal polyp size and nasal obstruction versus placebo.
- Nasal Polyp Score (NPS): At 52 weeks, the treatment difference was -0.7 (95% CI: -0.9, -0.4), p<0.001.
- Nasal Obstruction: Mean scores over weeks 49-52 showed a treatment difference of -0.24 (95% CI: -0.39, -0.08), p=0.003.
- Secondary Endpoints: Significant improvements were observed in rhinorrhoea, loss of smell, Lund-Mackay CT scores, and SNOT-22 quality of life measures.
- Intervention Avoidance: By week 52, 74% of depemokimab patients avoided systemic corticosteroids (SCS), surgery, or disease-modulating medication compared to 64% in the placebo group (p=0.006).
- Safety Profile: Adverse event rates were similar between depemokimab and placebo groups (74-76% vs. 79-80%). Less than 1% of depemokimab patients discontinued due to adverse events. No serious adverse events were considered related to the study treatment.
Guidance, Outlook, and Risks
Outlook and Regulatory Strategy: GSK intends to use findings from ANCHOR-1, ANCHOR-2, and prior asthma trials (SWIFT-1 and SWIFT-2) to support regulatory filings for both asthma with type 2 inflammation and CRSwNP globally. Depemokimab is not currently approved in any country.
Management Commentary: Kaivan Khavandi, SVP and Global Head of Respiratory, Immunology/Inflammation R&D, highlighted the medical need for alternatives to repeat surgeries and long-term corticosteroids, noting that depemokimab offers sustained symptom improvement with a twice-yearly dosing regimen.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks described in GSK's Annual Reports on Form 20-F for 2023 and 2024, including regulatory approval uncertainties and clinical trial outcomes.
Investor Verification Checklist
- Verify the timeline for regulatory submissions for depemokimab in CRSwNP and asthma indications.
- Confirm the commercial potential of the CRSwNP market and competitive landscape for IL-5 inhibitors.
- Review the safety data from the SWIFT-1 and SWIFT-2 asthma trials to assess the broader safety profile of depemokimab.
- Monitor upcoming FDA or EMA guidance on the acceptance of the pooled analysis data for approval.
- Check for any updates on the NIMBLE trial comparing depemokimab to mepolizumab or benralizumab in severe asthma.